Gilead applauds Quebec's Ministry of Health for expanding access to curative hepatitis C therapies to all diagnosed patients, regardless of severity of illness Quebec's expanded access includes EPCLUSA®, a 12 week treatment for patients with chronic hepatitis C across all six genotypes Gilead's new product, VOSEVI™ is now available on the List of Medications The removal of the fibrosis level criterion for access furthers Canada's co...
This is a must read article from Lucinda Porter, RN and the HCV Advocate. My first article for the HCV Advocate appeared 20 years ago. Hepatitis C virus infection (HCV) wasn’t curable yet. HCV is now easily curable and one would think the problem is solved, but it isn’t. Numerous obstacles stand in the way of eliminating this disease. A large percentage of the population is still undiagnosed because of inadequate HCV screening. Access to health care is u
Friday, March 9, 2018 News Recap: Canada: Northern Vancouver Island VIRAL HEPATITIS Outreach Roadshow Trip 2018 – March 12 – 21, 2018. We are happy to announce that a 10-day roadtrip to northern Vancouver Island is just around the corner! We will be bringing hot-off-the-press posters, pamphlets, and audio-visual resources to community organizations and Friendship Centres, band health centres, and health clinics. See links to some of the resources we...
Health-care practitioners say the lack of treatment options for provincial inmates with hepatitis C is creating inequities in health care and missing an opportunity to control the spread of the disease. Treatment for non-incarcerated Nova Scotians is publicly available. Dr. Lisa Barrett is an infectious disease doctor who sees inmates with HIV and hepatitis C at the Central Nova Scotia Correctional Facility in Dartmouth, N.S. She said when she sees
March 12 – 21, 2018 - HepCBC Hepatitis C Education & Prevention Society HepCBC Hepatitis C Education and Prevention Society sends small teams of nurses and peer navigators (mostly retired volunteers) into rural and remote parts of British Columbia to distribute resources and share information about local needs and the latest treatment for viral hepatitis: hep B (HBV) and hep C (HCV). We are happy to announce that a 10-day roadtrip to northern Vanco
People who received kidneys from donors infected with hepatitis C did not become ill with the virus, thanks to treatment with newer drugs that can cure the disease, a small study reports. Ten patients not previously infected with hepatitis C took doses of powerful antiviral medications before and after receiving the transplants. None of the patients developed chronic infections, researchers report online March 6 in the Annals of Internal Medicine. The fin
Tenofovir disoproxil fumarate (TDF), an antiviral drug commonly prescribed to treat hepatitis B infection, does not significantly reduce mother-to-child transmission of hepatitis B virus when taken during pregnancy and after delivery, according to a phase III clinical trial in Thailand funded by the National Institutes of Health. The study tested TDF therapy in addition to the standard preventative regimen — administration of hepatitis B vaccine and prote
A couple were arrested anew on suspicion of selling a counterfeit version of the hepatitis C drug Harvoni to a wholesaler. The Metropolitan Police Department arrested Yoshimi Kase, 49, and her husband, Takayuki, 43, on suspicion of violating the pharmaceuticals and medical devices law. The two, who had already been indicted for the use of illegal drugs, denied the fresh allegations and claimed their products were genuine, according to investigative sou
Changes spurred by development of minimally invasive drugs with extremely high cure rates. Health professionals are voicing excitement about new changes regarding the availability of hepatitis C treatment under Ontario's Drug Benefit program. The Ontario government says it will cover the cost of medication for all hepatitis C patients, regardless of the severity of the disease, a move that's being touted as a game-changing decision by health professionals
Prior to the introduction of effective prophylactic therapy, liver transplantation in patients infected with hepatitis B virus (HBV) resulted in high rates of viral recurrence, allograft loss, and mortality. One retrospective study found the risk of HBV recurrence to be as high as 75% in liver transplant patients who were not given immunoprophylaxis. Therapeutic advances in the past 2 decades have drastically changed the outlook for patients infected wi